Company XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for XOMA Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-31 EDT			5-day change	1st Jan Change
25.08 ^USD	-0.98%		-0.08%	-0.16%

05-09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT
05-09	XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).

Number of employees: 13

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	6	100.0 %	5	100.0 %	-21.06%

USD in Million	2022	Weight	2023	Weight	Delta
United States 76.9 %	4	74.3 %	4	76.9 %	-18.29%
Asia Pacific 23.1 %	2	25.7 %	1	23.1 %	-29.03%

Managers	Title	Age	Since
Owen Hughes CEO	Chief Executive Officer	49	22-12-31
Thomas Burns DFI	Director of Finance/CFO	50	06-08-13
Bradley Sitko CIO	Chief Investment Officer	43	23-01-02
Juliane Snowden IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Heather Franklin BRD	Director/Board Member	58	21-08-05
Jack Wyszomierski CHM	Chairman	68	10-08-25
Joseph Limber BRD	Director/Board Member	71	12-12-11
Matthew Perry BRD	Director/Board Member	51	17-02-15
Barbara Kosacz BRD	Director/Board Member	66	18-12-31
Owen Hughes CEO	Chief Executive Officer	49	22-12-31
Natasha Hernday BRD	Director/Board Member	52	20-06-29

	Vote	Quantity	Free-Float	Total Float
Stock A	0	984,000	0	99.47 %
Stock B	1	11,638,553	11,578,836 ( 99.49 %)
Stock C	0	1,600	0

Name	Equities	%	Valuation
BVF, Inc. 31.22 %	3,633,743	31.22 %	92 M $
Fidelity Management & Research Co. LLC 9.972 %	1,160,600	9.972 %	29 M $
BlackRock Advisors LLC 3.961 %	460,957	3.961 %	12 M $
Vanguard Fiduciary Trust Co. 3.484 %	405,533	3.484 %	10 M $
Stonepine Capital Management LLC 2.180 %	253,770	2.180 %	6 M $
Opaleye Management, Inc. 2.148 %	250,000	2.148 %	6 M $
Geode Capital Management LLC 1.461 %	170,049	1.461 %	4 M $
Morgan Stanley Investment Management, Inc. 1.368 %	159,183	1.368 %	4 M $
STATE STREET CORPORATION 1.194 %	138,949	1.194 %	4 M $
Acuitas Investments LLC 1.059 %	123,197	1.059 %	3 M $

Name	Equities	%	Valuation
Owen Hughes 0.1250 %	2,000	0.1250 %	50 000 $
Bradley Sitko 0.1250 %	2,000	0.1250 %	50 000 $

Name	Equities	%	Valuation
BVF Partners LP 100.00 %	5,003	100.00 %	126 876 $

Name	Equities	%	Valuation
BVF Partners LP 20.33 %	200,000	20.33 %	5 M $

XOMA Corp.

2200 Powell Street Suite 310

94608, Emeryville

+510 204 7200

http://www.xoma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.79 USD

Average target price

58 USD

Spread / Average Target

+124.89%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs